← Leaderboards
Jack C Sipe
Scripps Research Institute
$1,266,644
Attributed
$1,266,644
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $281.6K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,266,644 · 5
By mechanism
R01$838,034 · 1
R21$372,110 · 1
M01$56,500 · 3
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- John Johnson$22,284,193
- Ernest Beutler$10,050,147
- Donald D Stevenson$1,129,759
- Robert I Fox$54,722
- Vance D Rodgers$27,361
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationMultiple SclerosisHuman SubjectDrug Screening /EvaluationChlorodeoxyadenosineClinical ResearchNervous System Disorder ChemotherapyGene MutationDrug AbuseAmidesBaseAddictive BehaviorBasic ScienceBehaviorCannabinoidsCannabisAutomobile DrivingBody Measure ProcedureBody FatArtificial ImmunosuppressionBody WeightCandidate Disease GeneAmericanAddiction, Drug
Grant awards (10)
ENDOCANNABINOID BIOMARKERS OF OBESITY USING INTEGRATED GENOMICS AND METABOLOMICS$185,710
R21 · FY2008 · DA · contact PI
ENDOCANNABINOID BIOMARKERS OF OBESITY USING INTEGRATED GENOMICS AND METABOLOMICS$186,400
R21 · FY2007 · DA · contact PI
FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION$274,934
R01 · FY2006 · DA · contact PI
FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION$281,550
R01 · FY2005 · DA
FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION$281,550
R01 · FY2004 · DA
2-CdA for chronic progressive multiple sclerosis$1,778
M01 · FY2004 · RR
2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS$0
M01 · FY2002 · RR
2-CHLORODEOXYADENOSINE (2CDA) FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS$0
M01 · FY2002 · RR
2-CHLORODEOXYADENOSINE (2CDA) FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS$27,361
M01 · FY2000 · RR
2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS$27,361
M01 · FY2000 · RR